Results 131 to 140 of about 9,340 (184)

Biologic therapies for severe pediatric asthma: efficacy, safety, and biomarker-guided selection. [PDF]

Front Allergy
Tondina E, Codazzi AC, Castorina R, Di Micco R, Dutto C, Leoncini Bartoli L, Lepore G, Marseglia GL, Brambilla I.   +8 more
europepmc   +1 more source

Can Coexisting Allergic Rhinitis in Patients with Severe Eosinophilic Asthma Be a Prognostic Factor for Efficacy of Biological Therapy? Analysis of Eosinophilic Involvement. [PDF]

J Clin Med
Jura-Szołtys E, Glück J, Klimek L, Gawlik R.   +3 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial

Lancet Respiratory Medicine,the, 2021
BACKGROUND Chronic rhinosinusitis with nasal polyps affects approximately 2-4% of the general population, and long-term use of systemic corticosteroids is associated with adverse effects.
Claus Bachert, Wytske J Fokkens, Martin Desrosiers   +2 more
exaly   +2 more sources

Mepolizumab to Prevent Exacerbations of COPD with an Eosinophilic Phenotype

New England Journal of Medicine
BACKGROUND Mepolizumab is a humanized monoclonal antibody that targets interleukin-5, a cytokine that plays a central role in eosinophilic inflammation, which is present in 20 to 40% of patients with chronic obstructive pulmonary disease (COPD ...
Frank C. Sciurba, G. Criner, Stephanie A. Christenson, Fernando J. Martinez, A. Papi, Nicolas Roche, J. Bourbeau, Stephanie Korn, Mona Bafadhel, MeiLan K. Han, Stefanie Kolterer, Karen Miller, Dalal Mouneimne, J. Fletcher, B. Mayer, J. Min, I. Pavord   +16 more
exaly   +2 more sources

Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis

New England Journal of Medicine
BACKGROUND Eosinophilic granulomatosis with polyangiitis (EGPA) is a vasculitis characterized by eosinophilic inflammation. Benralizumab, a monoclonal antibody against the interleukin-5α receptor expressed on eosinophils, may be an option for treating ...
Michael E. Wechsler, P. Nair, B. Terrier, Bastian Walz, A. Bourdin, D. Jayne, D. J. Jackson, F. Roufosse, L. Börjesson Sjö, Ying Fan, M. Jison, C. Mccrae, S. Necander, A. Shavit, C. Walton, Peter A. Merkel   +15 more
exaly   +2 more sources

Mepolizumab for treatment of adolescents and adults with eosinophilic oesophagitis: a multicentre, randomised, double-blind, placebo-controlled clinical trial

Gut, 2023
Objective We aimed to determine whether mepolizumab, an anti-IL-5 antibody, was more effective than placebo for improving dysphagia symptoms and decreasing oesophageal eosinophil counts in eosinophilic oesophagitis (EoE).
Evan Dellon, Ikuo Hirano
exaly   +2 more sources

Mepolizumab

Reactions Weekly, 2022
  +10 more sources

Mepolizumab versus benralizumab for eosinophilic granulomatosis with polyangiitis (EGPA): A European real-life retrospective comparative study.

Journal of Autoimmunity
BACKGROUND Following the results of the MANDARA trial, this real-life study aimed at comparing the effectiveness and safety profile of mepolizumab versus benralizumab in a European EGPA cohort.
I. Mattioli, M. Urban, R. Padoan, Aladdin J. Mohammad, Carlo Salvarani, Chiara Baldini, A. Berti, P. Cameli, M. Caminati, P. Cathébras, F. C. Bianchi, F. Cinetto, Jan Willem Cohen Tervaert, A. Coppola, G. Costanzo, V. Cottin, C. Crimi, S. Del Giacco, C. Desaintjean, A. Egan, G. Espígol-Frigolé, M. Folci, M. Fornaro, F. Franceschini, M. Govoni, Matthieu Groh, G. Guarnieri, B. Hellmich, F. Iannone, Rachel B Jones, A. Kernder, Alberto Lo Gullo, C. Lombardi, G. Lopalco, L. Losappio, M. Marchi, Carlos Martinez Rivera, C. Marvisi, M. Maule, Laura Moi, Sara Monti, F. Moosig, Gianluca Moroncini, Simone Negrini, T. Neumann, S. Nolasco, Pavel Novikov, D. Roccatello, Maxime Samson, J. Schroeder, B. Seeliger, R. Sinico, R. Solans, C. Tcherakian, P. Toniati, E. Treppo, Giorgio Trivioli, Angelo Vacca, David R Jayne, Alessandra Bettiol, Augusto Vaglio, Giacomo Emmi   +61 more
semanticscholar   +1 more source

Mepolizumab in chronic rhinosinusitis with nasal polyps: Real life data in a multicentric Sicilian experience.

American Journal of Otolaryngology
BACKGROUND Chronic rhinosinusitis with nasal polyps (CRSwNP) is characterized by a type 2 pattern of inflammation. Mepolizumab was approved for the treatment of CRSwNP in 2021. However, there is a lack of real-life studies.
C. Galletti, F. Sireci, Giovanna Stilo, Maria Antonietta Barbieri, Giuliano Messina, Riccardo Manzella, D. Portelli, Andrea Guglielmo Zappalà, Mariut Diana, Silvia Frangipane, Angelo Immordino, F. Lorusso, Francesco Dispensa, Francesco Ciodaro, F. Freni, Francesco Galletti, Salvatore Gallina, I. La Mantia, Bruno Galletti   +18 more
semanticscholar   +1 more source